Literature DB >> 9491784

Effects of angiotensin II on bone cells in vitro.

S Lamparter1, L Kling, M Schrader, R Ziegler, J Pfeilschifter.   

Abstract

Other than its known effects on the cardiovascular system, angiotensin II (Ang II) stimulates cell growth in several cell types. In this study, we examined whether it also might affect bone cell metabolism. Ang II stimulated DNA and collagen synthesis and decreased alkaline phosphatase (AP) activity in bone cell populations derived from the periosteum of fetal rat calvariae. Similar effects of Ang II were observed on human adult bone cells obtained by collagenase digestion from trabecular bone. Clonal cell analysis, autoradiographic studies, and receptor subtype analysis suggested the presence of specific Ang II receptor subtype 1 (AT1) binding sites on AP+ osteoblastic precursor cells. Ang II had no direct effects on osteoblastic cells with a mature phenotype, but paracrine effects of Ang II on mature osteoblasts could be observed upon coculture with Ang II-responsive bone cell populations. Because Ang II is known to be locally generated by endothelial cells, Ang II might play an important role in coordinating capillary cell growth and osteoblastic bone formation during bone remodeling.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9491784     DOI: 10.1002/(SICI)1097-4652(199804)175:1<89::AID-JCP10>3.0.CO;2-J

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  10 in total

1.  Enhanced angiotensin-converting enzyme 2 attenuates angiotensin II-induced collagen production via AT1 receptor-phosphoinositide 3-kinase-Akt pathway.

Authors:  Le Bu; Shen Qu; Xiang Gao; J-J Zou; Wei Tang; L-L Sun; Z-M Liu
Journal:  Endocrine       Date:  2010-12-28       Impact factor: 3.633

2.  Long-term use of angiotensin-converting enzyme inhibitors protects against bone loss in African-American elderly men.

Authors:  Nahid Rianon; Catherine G Ambrose; Hannah Pervin; Melissa Garcia; Scherezade K Mama; Ann V Schwartz; Brendan Lee; Tamara Harris
Journal:  Arch Osteoporos       Date:  2017-10-28       Impact factor: 2.617

3.  Renin inhibitor aliskiren exerts beneficial effect on trabecular bone by regulating skeletal renin-angiotensin system and kallikrein-kinin system in ovariectomized mice.

Authors:  Y Zhang; L Wang; Y Song; X Zhao; M S Wong; W Zhang
Journal:  Osteoporos Int       Date:  2015-10-06       Impact factor: 4.507

4.  Captopril improves osteopenia in ovariectomized rats and promotes bone formation in osteoblasts.

Authors:  Yu Yu Liu; Wei Min Yao; Tie Wu; Bi Lian Xu; Fang Chen; Liao Cui
Journal:  J Bone Miner Metab       Date:  2010-08-06       Impact factor: 2.626

Review 5.  Genetics of otosclerosis: finally catching up with other complex traits?

Authors:  Lisse J M Tavernier; Erik Fransen; Hanne Valgaeren; Guy Van Camp
Journal:  Hum Genet       Date:  2021-09-09       Impact factor: 4.132

6.  Angiotensin II reduces calcium uptake into bone.

Authors:  Scott J Schurman; William H Bergstrom; Lawrence R Shoemaker; Thomas R Welch
Journal:  Pediatr Nephrol       Date:  2003-11-25       Impact factor: 3.714

7.  Endothelin but Not Angiotensin II May Mediate Hypertension-Induced Coronary Vascular Calcification in Chronic Kidney Disease.

Authors:  Simon W Rabkin
Journal:  Int J Nephrol       Date:  2011-05-31

8.  Angiotensin II suppresses osteoblastic differentiation and mineralized nodule formation via AT1 receptor in ROS17/2.8 cells.

Authors:  Kumiko Nakai; Takayuki Kawato; Toyoko Morita; Yoji Yamazaki; Hideki Tanaka; Morio Tonogi; Hidero Oki; Masao Maeno
Journal:  Arch Med Sci       Date:  2015-06-19       Impact factor: 3.318

9.  Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies.

Authors:  Setor K Kunutsor; Ashley W Blom; Michael R Whitehouse; Patrick G Kehoe; Jari A Laukkanen
Journal:  Eur J Epidemiol       Date:  2017-07-27       Impact factor: 8.082

Review 10.  Potential of RAS inhibition to improve metabolic bone disorders.

Authors:  Yoseph Gebru; Teng-Yue Diao; Hai Pan; Emmanuel Mukwaya; Yan Zhang
Journal:  Biomed Res Int       Date:  2013-07-22       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.